RLAY Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.9% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Relay Therapeutics, Inc.
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients.
Sector
Healthcare
Industry
Biotechnology